Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of D-Glutamate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 known ✓ | P39086 | 1/20 | 0.95 |
| ▸ | GRIA1 known ✓ | P42261 | 1/20 | 0.95 |
| ▸ | GRIA2 known ✓ | P42262 | 1/20 | 0.95 |
| ▸ | GRIA3 known ✓ | P42263 | 1/20 | 0.95 |
| ▸ | GRIA4 known ✓ | P48058 | 1/20 | 0.95 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.95 |
| ▸ | GRIK2 known ✓ | Q13002 | 1/20 | 0.95 |
| ▸ | GRIK3 known ✓ | Q13003 | 1/20 | 0.95 |
| ▸ | GRIK5 known ✓ | Q16478 | 1/20 | 0.95 |
| ▸ | GRM8 | O00222 | 2/20 | 0.95 |
| ▸ | GRM6 | O15303 | 2/20 | 0.95 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.95 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.95 |
| ▸ | GSR | P00390 | 2/20 | 0.95 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.95 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.95 |
| ▸ | GRM5 | P41594 | 1/20 | 0.95 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.95 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL28352293 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL8530554 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL1086195 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL5605822 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL5605825 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL8530551 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL5605604 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL910049 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| Glutamic Acid SCHEMBL5605606 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR | |
| D-Glutamate SCHEMBL28352296 | 1.00 | GRM8 (0.95) | GRM8GRM6GRM7GRM4GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2010529198-A | — | — | 2010-08-26 | — | — | JP | claimed |
| US-20100209532-A1 | TARGETED OXYGEN DELIVERY VIA INTRAVENOUS OR INTRA-ARTERIAL INFUSION OF OXYGENATED POLYMERIZED HEMOGLOBIN SOLUTIONS | OPK BIOTECH LLC (US) | 2010-08-19 | — | — | US | claimed |
| EP-2170371-A1 | TARGETED OXYGEN DELIVERY VIA INTRAVENOUS OR INTRA-ARTERIAL INFUSION OF OXYGENATED POLYMERIZED HEMOGLOBIN SOLUTIONS | OPK Biotech LLC (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2008156699-A1 | TARGETED OXYGEN DELIVERY VIA INTRAVENOUS OR INTRA-ARTERIAL INFUSION OF OXYGENATED POLYMERIZED HEMOGLOBIN SOLUTIONS | BIOPURE CORPORATION (US) | 2008-12-24 | — | — | WO | claimed |
| US-12343342-B2 | Methods for treating soft tissue sarcoma | LIXTE BIOTECHNOLOGY, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-2983661-B1 | FORMULATIONS OF OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES | LIXTE BIOTECHNOLOGY INC (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980473-A | Organisms producing less crotonic acid | 环球生物能源公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117965415-A | Method for promoting microbial denitrification and synergistic carbon reduction | 同济大学 | 2024-05-03 | — | — | CN | disclosed |
| US-11931354-B2 | Formulations of oxabicycloheptanes and oxabicycloheptenes | LIXTE BIOTECHNOLOGY, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240041864-A1 | METHODS FOR TREATING SOFT TISSUE SARCOMA | LIXTE BIOTECHNOLOGY, INC. | 2024-02-08 | — | — | US | disclosed |
| CN-113454198-A | Composition for removing chemical residues and use thereof | 普里沃国际公司 | 2021-09-28 | — | — | CN | disclosed |
| US-10865362-B2 | Process for manufacturing MGDA/GLDA granules, granules, and their use | BASF SE (DE) | 2020-12-15 | — | — | US | disclosed |
| EP-3484988-A1 | PROCESS FOR MANUFACTURING OF MGDA AND GLDA CONTAINING GRANULES, THE GRANULES AND THEIR USE | BASF SE (DE) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018011027-A1 | PROCESS FOR MANUFACTURING OF MGDA AND GLDA CONTAINING GRANULES, THE GRANULES AND THEIR USE | BASF SE (DE) | 2018-01-18 | — | — | WO | disclosed |
| CN-105982914-A | Novel pharmaceutical composition of compound amino acid injection 18AA-I and application of pharmaceutical composition | 刘力 | 2016-10-05 | — | — | CN | disclosed |
| US-20100209532-A1 | TARGETED OXYGEN DELIVERY VIA INTRAVENOUS OR INTRA-ARTERIAL INFUSION OF OXYGENATED POLYMERIZED HEMOGLOBIN SOLUTIONS | OPK BIOTECH LLC (US) | 2010-08-19 | — | — | US | disclosed |
| EP-2170371-A1 | TARGETED OXYGEN DELIVERY VIA INTRAVENOUS OR INTRA-ARTERIAL INFUSION OF OXYGENATED POLYMERIZED HEMOGLOBIN SOLUTIONS | OPK Biotech LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156699-A1 | TARGETED OXYGEN DELIVERY VIA INTRAVENOUS OR INTRA-ARTERIAL INFUSION OF OXYGENATED POLYMERIZED HEMOGLOBIN SOLUTIONS | BIOPURE CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-4952706-A | TRIHYDRATES OF SODIUM PYROGLUTAMATE ENANTIOMORPHS | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1990-08-28 | — | — | US | disclosed |
| US-4035513-A | COSMETICS | SHISEIDO CO., LTD. (JA) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12343342-B2 | Methods for treating soft tissue sarcoma | PPP2CA, PPM1A, PPP2R2A | GRIK1 130/4885GRIA1 205/4885GRIA2 114/4885 |
| US-20240041864-A1 | METHODS FOR TREATING SOFT TISSUE SARCOMA | PPP2CA, PPM1A, PPP2R2A | GRIK1 130/4885GRIA1 205/4885GRIA2 114/4885 |
| US-11931354-B2 | Formulations of oxabicycloheptanes and oxabicycloheptenes | PPP2CA, PPP2R2A, PPM1A | GRIK1 85/4885GRIA1 66/4885GRIA2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.